Experimental: GLP1-RA (exenatide) administration ( DrugBank: Exenatide )


2 diseases
IDDisease name (Link within this page)Number of trials
72Pituitary ADH secretion disorder1
78Hypopituitarism1

72. Pituitary ADH secretion disorder


Clinical trials : 40 Drugs : 28 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 9
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04897802
(ClinicalTrials.gov)
September 13, 202117/5/2021Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin DeficiencyDrug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administrationFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauInstituto de Salud Carlos IIIRecruiting18 Years65 YearsAll52Phase 4Spain

78. Hypopituitarism


Clinical trials : 494 Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04897802
(ClinicalTrials.gov)
September 13, 202117/5/2021Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin DeficiencyDrug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administrationFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauInstituto de Salud Carlos IIIRecruiting18 Years65 YearsAll52Phase 4Spain